The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Boehringer Ingelheim’s nintedanib for the treatment of systemic sclerosis with associated interstitial lung disease (SSc-ILD).    This designation is based on Boehringer Ingelheim’s Investigational New Drug application (IND) of nintedanib for the treatment of SSc-ILD and the anticipated efficacy and safety data from SENSCIS™ (Safety and Efficacy of Nintedanib in Systemic SClerosIS), a double-blind, ra...